255 related articles for article (PubMed ID: 19584274)
1. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
Surguladze D; Deevi D; Claros N; Corcoran E; Wang S; Plym MJ; Wu Y; Doody J; Mauro DJ; Witte L; Busam KJ; Pytowski B; Rodeck U; Tonra JR
Cancer Res; 2009 Jul; 69(14):5643-7. PubMed ID: 19584274
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice.
Sugihara T; Okiyama N; Watanabe N; Miyasaka N; Kohsaka H
Arthritis Rheum; 2012 Aug; 64(8):2655-62. PubMed ID: 22392010
[TBL] [Abstract][Full Text] [Related]
3. Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice.
Grounds MD; Davies M; Torrisi J; Shavlakadze T; White J; Hodgetts S
Cell Tissue Res; 2005 Jun; 320(3):509-15. PubMed ID: 15846506
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model.
Choi B; Hwang Y; Kwon HJ; Lee ES; Park KS; Bang D; Lee S; Sohn S
J Dermatol Sci; 2008 Nov; 52(2):87-97. PubMed ID: 18585901
[TBL] [Abstract][Full Text] [Related]
5. Systemic inflammation sensitizes the neonatal brain to excitotoxicity through a pro-/anti-inflammatory imbalance: key role of TNFalpha pathway and protection by etanercept.
Adén U; Favrais G; Plaisant F; Winerdal M; Felderhoff-Mueser U; Lampa J; Lelièvre V; Gressens P
Brain Behav Immun; 2010 Jul; 24(5):747-58. PubMed ID: 19861157
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha-stimulated membrane type 1-matrix metalloproteinase production is modulated by epidermal growth factor receptor signaling in human gingival fibroblasts.
Smith PC; Guerrero J; Tobar N; Cáceres M; González MJ; Martínez J
J Periodontal Res; 2009 Feb; 44(1):73-80. PubMed ID: 19515020
[TBL] [Abstract][Full Text] [Related]
7. TNFalpha antagonist upregulates interleukin-6 in rats with hypertensive heart failure.
Haugen E; Täng MS; Isic A; Andersson B; Fu M
Int J Cardiol; 2008 Oct; 130(1):64-8. PubMed ID: 18280594
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target.
Boettger MK; Hensellek S; Richter F; Gajda M; Stöckigt R; von Banchet GS; Bräuer R; Schaible HG
Arthritis Rheum; 2008 Aug; 58(8):2368-78. PubMed ID: 18668541
[TBL] [Abstract][Full Text] [Related]
9. Fever pitch.
Ledford H
Nature; 2007 Nov; 450(7170):600-1. PubMed ID: 18046368
[No Abstract] [Full Text] [Related]
10. Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?
Rodeck U
J Cell Physiol; 2009 Jan; 218(1):32-4. PubMed ID: 18781585
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human soluble tumor necrosis factor-alpha receptor fusion protein partly attenuates ventilator-induced lung injury.
Wolthuis EK; Vlaar AP; Choi G; Roelofs JJ; Haitsma JJ; van der Poll T; Juffermans NP; Zweers MM; Schultz MJ
Shock; 2009 Mar; 31(3):262-6. PubMed ID: 18650784
[TBL] [Abstract][Full Text] [Related]
12. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
Sweiss NJ; Curran J; Baughman RP
Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312
[TBL] [Abstract][Full Text] [Related]
13. Etanercept reduces acute tissue injury and mortality associated to zymosan-induced multiple organ dysfunction syndrome.
Malleo G; Mazzon E; Genovese T; Di Paola R; Muià C; Caminiti R; Esposito E; Di Bella P; Cuzzocrea S
Shock; 2008 May; 29(5):560-71. PubMed ID: 17724436
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E(2)-EP(3) signaling suppresses skin inflammation in murine contact hypersensitivity.
Honda T; Matsuoka T; Ueta M; Kabashima K; Miyachi Y; Narumiya S
J Allergy Clin Immunol; 2009 Oct; 124(4):809-18.e2. PubMed ID: 19541354
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation.
Satoh H; Firestein GS; Billings PB; Harris JP; Keithley EM
Laryngoscope; 2002 Sep; 112(9):1627-34. PubMed ID: 12352677
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 10 regulates inflammatory cytokine synthesis to protect against lipopolysaccharide-induced abortion and fetal growth restriction in mice.
Robertson SA; Care AS; Skinner RJ
Biol Reprod; 2007 May; 76(5):738-48. PubMed ID: 17215490
[TBL] [Abstract][Full Text] [Related]
17. Involvement of tumor necrosis factor (TNF)-alpha in phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin edema in mice.
Murakawa M; Yamaoka K; Tanaka Y; Fukuda Y
Biochem Pharmacol; 2006 Apr; 71(9):1331-6. PubMed ID: 16487490
[TBL] [Abstract][Full Text] [Related]
18. Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms.
Kim MS; Lee SH; Song MY; Yoo TH; Lee BK; Kim YS
J Mol Biol; 2007 Dec; 374(5):1374-88. PubMed ID: 17996896
[TBL] [Abstract][Full Text] [Related]
19. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.
Grattendick KJ; Nakashima JM; Feng L; Giri SN; Margolin SB
Int Immunopharmacol; 2008 May; 8(5):679-87. PubMed ID: 18387510
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.
Egberts JH; Cloosters V; Noack A; Schniewind B; Thon L; Klose S; Kettler B; von Forstner C; Kneitz C; Tepel J; Adam D; Wajant H; Kalthoff H; Trauzold A
Cancer Res; 2008 Mar; 68(5):1443-50. PubMed ID: 18316608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
